New drug law gives AG power to ban substances without court review
S. 3228 — SIMSA Act of 2025 · Filed by Chuck Grassley (R-IA) · 4 cosponsors · Introduced Nov 20, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill creates a new 'Schedule A' category in the Controlled Substances Act to regulate synthetic drug analogues—chemical variants of illegal drugs designed to evade existing laws. The Attorney General gains power to temporarily ban substances for up to 5 years (with 30-day notice) and then make permanent bans, based on chemical similarity and predicted effects. Violations carry up to 20 years imprisonment (30 years if there's a prior drug conviction, or life if death results), plus mandatory supervised release and fines up to $1–5 million. The bill also requires proper chemical labeling of Schedule A substances and allows researchers to continue work on newly scheduled drugs under certain conditions.
Why we flagged it
The bill's core mechanism is creating a new regulatory schedule and enforcement authority for synthetic drug analogues. While framed as a public-health measure, it is fundamentally an expansion of executive power to criminalize substances with minimal procedural safeguards and severe mandatory penalties.
What the text implies
- The 'predicted' effect standard (based on chemical structure, structure-activity relationships, or binding assays) is subjective and may allow the Attorney General to schedule substances without empirical evidence of actual abuse or harm, potentially capturing legitimate research chemicals or industrial compounds.
- Temporary scheduling orders are explicitly exempt from judicial review (Section 3(4)), meaning defendants cannot challenge the legality of a ban in court before prosecution—a significant due-process gap compared to other CSA schedules.
The full analysis lists 5 implications of this text.
Who it affects
The bill addresses a genuine public-health problem—synthetic drug analogues that circumvent existing law—and creates a faster regulatory pathway than current procedures. However, it grants the Attorney General broad power to ban substances with minimal judicial review (temporary orders are not reviewable), creates severe mandatory penalties that may not fit all offenses, and relies on 'predicted' effects that could be applied expansively, raising due-process concerns for defendants and legitimat